Integra Lifesciences (NASDAQ: IART) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Risk and Volatility
Integra Lifesciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Illumina has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
This table compares Integra Lifesciences and Illumina’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Integra Lifesciences and Illumina’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Integra Lifesciences||$1.19 billion||4.76||$64.74 million||$1.94||33.20|
|Illumina||$2.75 billion||14.92||$726.00 million||$4.00||69.82|
Illumina has higher revenue and earnings than Integra Lifesciences. Integra Lifesciences is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
79.5% of Integra Lifesciences shares are held by institutional investors. Comparatively, 90.5% of Illumina shares are held by institutional investors. 5.1% of Integra Lifesciences shares are held by company insiders. Comparatively, 0.5% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for Integra Lifesciences and Illumina, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Integra Lifesciences presently has a consensus target price of $60.00, indicating a potential downside of 6.85%. Illumina has a consensus target price of $258.00, indicating a potential downside of 7.62%. Given Integra Lifesciences’ higher possible upside, equities research analysts plainly believe Integra Lifesciences is more favorable than Illumina.
Illumina beats Integra Lifesciences on 13 of the 15 factors compared between the two stocks.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.